Treatment 9 min
Metastatic melanoma treatment: what options are there today
Why BRAF testing matters, how immunotherapy regimens differ, when targeted therapy is used, how stage III and brain metastases are treated, how long it lasts.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 16 October 2026
In metastatic melanoma, the backbone of treatment today is immunotherapy with checkpoint inhibitors, and for tumors with a BRAF mutation there are also targeted tablets. Some patients with stage IV disease live for many years, so the choice of first-line treatment and the order of treatments really matters.
Where it starts: testing for a BRAF mutation
The first thing you need to know about your melanoma is whether it has a mutation in the BRAF gene (most often the V600 variant). According to the American Cancer Society, such changes are found in about half of all melanomas.
The result determines which treatment options are available:
- BRAF mutation present — both immunotherapy and targeted therapy (a combination of a BRAF inhibitor and a MEK inhibitor) are possible.
- No BRAF mutation — BRAF/MEK targeted therapy is not suitable, and treatment is based on immunotherapy.
The test is done on tumor tissue — from the removed primary tumor, a lymph node or a metastasis. That is why the paraffin blocks and slides need to be kept. I explained how molecular tests work in general in my article on targeted therapy.
Immunotherapy: three main options
In metastatic melanoma, immunotherapy is most often the first line. The drugs take the “brakes” off the immune system so that it attacks the tumor. I went through the mechanism and side effects in detail in my article on cancer immunotherapy. Here I’ll focus on the regimens used in melanoma.
| Regimen | What it is | What you should know |
|---|---|---|
| Anti-PD-1 alone (pembrolizumab or nivolumab) | A single drug | Easier to tolerate than combinations |
| PD-1 + CTLA-4 (nivolumab + ipilimumab) | Two drugs with different mechanisms | The most studied combination; according to the American Cancer Society, combinations seem to be more effective, but serious side effects are more common, especially because of ipilimumab |
| PD-1 + LAG-3 (nivolumab + relatlimab) | LAG-3 is another checkpoint on lymphocytes | Listed among first-line options by the American Cancer Society |
The longest data come from the CheckMate 067 trial, which compared nivolumab plus ipilimumab, nivolumab alone and ipilimumab alone. The final results after 10 years of follow-up were published in 2024:
- median overall survival was 71.9 months with the combination, 36.9 months with nivolumab and 19.9 months with ipilimumab;
- 10-year melanoma-specific survival was 52%, 44% and 23% respectively.
The median is the point by which half of the patients in a group are still alive. For an individual it predicts little, but it shows the difference between approaches well. And the most important thing these data show is that in some patients with stage IV disease, the illness stays under control for years.
Whether to choose a single drug or a combination is decided based on the patient’s general condition, the extent of the disease, whether there are brain metastases, other medical conditions and willingness to accept a higher risk of side effects. There is no simple answer that “the combination is always better”.
BRAF/MEK targeted therapy: when it is chosen
If the tumor has a BRAF mutation, targeted therapy is possible — a combination of a BRAF inhibitor and a MEK inhibitor taken as tablets. Its main advantage is rapid tumor shrinkage, which is why it is chosen when every week counts.
So why do doctors often start with immunotherapy even when BRAF is mutated? The DREAMseq trial (2022) gave the answer: among patients with BRAF-mutated melanoma who started with nivolumab and ipilimumab, 2-year survival was 71.8%, compared with 51.5% in those who started with targeted therapy. The authors concluded that for most patients the preferred sequence is “immunotherapy first, then BRAF/MEK if needed”.
Targeted therapy is chosen first when the tumor needs to shrink quickly — for example, with extensive metastases and significant symptoms — or when immunotherapy is contraindicated or its side effects cannot be tolerated.
Stage III: treatment before and after surgery
In stage III (metastases in lymph nodes or in-transit metastases in the skin), treatment is not limited to surgery.
Neoadjuvant therapy means drugs given before surgery. If lymph node involvement can be seen on examination or on scans, according to the American Cancer Society, immunotherapy or targeted therapy is often given first. The basis for this is the NADINA trial: patients received 2 courses of nivolumab with ipilimumab before surgery. At 12 months, 83.7% were alive without an event (recurrence, progression or death), compared with 57.2% in the group that had surgery first followed by nivolumab. Patients who still had a lot of viable tumor in the removed tissue after neoadjuvant therapy went on to receive further treatment after surgery.
Adjuvant therapy means drugs given after surgery to lower the risk of recurrence. PD-1 inhibitors are used, or, with a BRAF mutation, BRAF/MEK targeted therapy; the course usually lasts about a year. I explained the logic of treatment before and after surgery in a separate article on neoadjuvant and adjuvant therapy.
Brain metastases
Brain metastases are not uncommon in melanoma, and in the past they meant a very poor outlook. The approach is different now: both the deposits themselves are treated (surgery, stereotactic radiosurgery, sometimes whole-brain radiotherapy) and the disease as a whole is treated with drugs.
Immunotherapy works in the brain too. In the CheckMate 204 trial, patients with brain metastases and no neurological symptoms received nivolumab with ipilimumab: intracranial control (shrinkage or stabilization of the deposits) was achieved in 57.4%, and 3-year survival was 71.9%. In patients with symptoms, the results were noticeably worse: 16.7% and 36.6%. That is why a brain MRI is usually done when staging metastatic melanoma, even if you have no head symptoms.
Call your local emergency number (911 in the US, 999 in the UK, 112 in the EU) for seizures, a sudden severe headache, weakness in an arm or leg, speech problems or confusion. With brain metastases, this may be swelling or bleeding in a deposit, and help is needed immediately.
What a response looks like on PET-CT and how long treatment lasts
The response to treatment is assessed with CT, MRI and often PET-CT. On PET-CT, doctors look at whether the deposits take up radioactive glucose — that is, whether active tumor cells remain in them. A complete metabolic response means there is no more uptake. Sometimes CT still shows residual areas of thickening — scar changes where the metastases used to be.
A complete metabolic response is a strong prognostic sign. In data from Melanoma Institute Australia cited by The ASCO Post, among 114 patients with a complete response, about 95% were progression-free at 4 years if the response was confirmed on PET, and a little over 50% if it was not.
How long should treatment last? There is no clear answer from randomized trials. The usual practice is to continue immunotherapy for no longer than 2 years. With a complete response, treatment is sometimes stopped earlier. Trial data show that in most patients with a complete response, remission persists after treatment is stopped. If the disease comes back after stopping, immunotherapy can be given again.
The opposite happens too: progression on one treatment does not rule out a response to another. I described an example of this in my clinical case of stage IV melanoma — a complete metabolic response was achieved after progression on previous treatment.
Questions to ask your doctor
- Does my tumor have a BRAF mutation? If the test hasn’t been done, what material can it be done on?
- Why has a single drug or a combination been chosen for me?
- Do I need a brain MRI now?
- How will the response be assessed — CT or PET-CT, and after how long?
- How long is treatment planned for, and what result would allow it to be stopped?
- Which symptoms need a same-day call?
If you are being treated for melanoma and want to make sense of PET-CT results, side effects or options for the next line of treatment, we can discuss this at an online consultation — after our conversation, I’ll send you a written summary.
Sources
- Treatment of Melanoma Skin Cancer, by Stage — American Cancer Society, accessed 2026
- Survival Benefit Continues at 10 Years From Opdivo Either Alone or With Yervoy in Advanced Melanoma — CURE (final CheckMate 067 results, NEJM), 2024
- Nivolumab/Ipilimumab vs Dabrafenib/Trametinib With Switch at Disease Progression for Metastatic BRAF-Mutant Melanoma — The ASCO Post (DREAMseq, JCO), 2022
- Trial Updates in Stage III Melanoma Solidify the Neoadjuvant Use of Immunotherapy as the Current Standard of Care — The ASCO Post (NADINA), 2024
- Long-Term Outcomes With Nivolumab Plus Ipilimumab in Active Melanoma Brain Metastases — The ASCO Post (CheckMate 204, Lancet Oncology), 2021
- Optimal Duration of Checkpoint Inhibition in Melanoma Is No More Than 2 Years — The ASCO Post (ESMO 2018), 2018
Frequently asked questions
This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.
